Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. is a joint venture between Hong Kong Cell Valley (80% stake) and Shenzhen Cell Valley (20% stake). With a registered capital of RMB 100 million, the company is located in Phase II of the Qianhai Shenzhen-Hong Kong Youth Dream Factory in Nanshan District, Shenzhen, covering an area of over 1,100 square meters. The company specializes in the development of new cell and gene therapy (CGT) drugs, high-end medical services, precision medical testing, and the anti-aging and health care industries.
As one of the key investment projects for the Qianhai Free Trade Zone’s 10th anniversary, the company leverages Shenzhen Cell Valley’s strong R&D and technological foundation and Hong Kong Cell Valley’s abundant capital and international resources to advance the development of cell therapy drugs, personalized medical care, and health management services. Its business covers areas such as oncology, autoimmune diseases, degenerative geriatric diseases, and cancer prevention.
Based in Shenzhen, Shenzhen-Hong Kong Cell Valley will radiate to the Guangdong-Hong Kong-Macao Greater Bay Area, Southeast Asia, Europe, and the United States. It will strive to build a one-stop service platform centered on international cell therapy and health management. It will also actively expand into consumer healthcare sectors such as health and medical aesthetics, anti-aging, and establish an innovative development model driven by a dual focus of “medical care + consumer healthcare.”
Founding Team
Dr. Howard Shi – Chairman of the Group Board
Dr. Howard Shi is a Chinese-American scientist and the founder and Chairman of the Hong Kong Cell Valley Group. He possesses a distinguished scientific research background and extensive management experience.
Education and Academic Background
· PhD in Biochemistry and Molecular Biology, postdoctoral fellow in the Department of Medical Pathology at Harvard University.
· Former researcher at the Lovelace Respiratory Research Institute in the United States, and professor, doctoral supervisor, and postdoctoral supervisor at Beijing University of Chinese Medicine. He founded the School of Life Sciences at Beijing University of Chinese Medicine and the Shenzhen Institute of Chinese Medicine, and served as its founding dean.
Project and Policy Leadership
· Leads the Shenzhen Overseas High-Level Talent Team Program.
· Intensively participated in legislative consultation on the “Regulations on the Promotion of the Cell and Gene Industry in the Shenzhen Special Economic Zone” and the “Regulations on the Promotion of the Cell and Gene Industry in the Xiamen Special Economic Zone,” providing professional support for policy formulation.
Business and Industry Influence
· Has extensive business management experience and has successfully founded Boston Health Technology Co., Ltd., Shenzhen Cell Valley Biopharmaceutical Co., Ltd., and Guangdong Junhou Biopharmaceutical Co., Ltd.
· Serves as a member of regulatory and standards committees such as the China Food and Drug Enterprise Quality and Safety Promotion Association, contributing professional wisdom to industry standardization and standard setting.
Academic and Educational Contributions
· Serves as a review expert for the “Changjiang Scholars” program of the Ministry of Education of China and an expert reviewer for the Ministry of Education’s fifth round of discipline evaluation, and enjoys a high reputation in the fields of education and scientific research.
Leadership Philosophy and Vision
As the founder of Hong Kong Cell Valley Group, Dr. Howard Shi is committed to providing patients with innovative, high-quality medical solutions through cutting-edge cell and gene therapy technologies, and promoting the development of the global cell and gene therapy field.
Dr. Jianxun Wang – Chief Scientist (CSO)
Dr. Jianxun Wang is a Chinese-American scientist and Chief Scientist of Hong Kong Cell Valley Group. He has extensive academic background and technical R&D experience, particularly in the field of cell and gene therapy.
Educational and Academic Background
· Received a PhD in Immunology and a postdoctoral fellowship from the University of California, San Diego (UCSD).
· Concurrently serves as a professor, doctoral supervisor, and postdoctoral supervisor at Beijing University of Chinese Medicine.
A pioneering scientist in the industrialized production of retroviral vectors in China.
Academic Research and Breakthroughs
Published numerous papers in world-class academic journals such as Nature. As an expert in epigenetics, he primarily explores how to leverage epigenetic alterations in T cells to enhance their ability to recognize and kill tumors, achieving breakthroughs in CAR-T therapy for solid tumors.
Business and Industry Contributions
Formerly a senior scientist at a renowned US pharmaceutical company, he established cGMP for CAR-T and possesses extensive experience in standardized industrialized cell therapy production.
A leading international expert in the development of retroviral vectors.
Serves as a member of the Expert Committee of the China Food and Drug Administration Quality and Safety Promotion Association.
Leadership Philosophy and Vision
As Chief Scientist of Hong Kong Cell Valley Group, Dr. Wang Jianxun is committed to promoting innovation and industrialization in cell and gene therapy technologies, providing safer and more efficient medical solutions for patients worldwide and accelerating the widespread adoption and application of cell therapy technologies.
Dr. David Kin Jin – Chief Medical Officer (CMO)
Dr. David Kin Jin is a Chinese-American medical expert born in Hong Kong. He is the Chief Medical Officer of Hong Kong Cell Valley Group. He has extensive clinical research experience and industry leadership, and is a practicing physician in the United States, specializing in oncology, general medicine, and cell therapy.
Education and Academic Background
· He holds dual doctorates (M.D. & Ph.D.) from the State University of New York College of Medicine.
· He previously served as professor and chief physician at Cornell University and Columbia University Medical School.
· He served as a senior researcher at the Ansary Stem Cell Institute at Cornell University Medical School, where he published over 30 peer-reviewed research and clinical papers.
Professional Achievements and Honors
· He previously served as a reviewer for oncology drug development at the U.S. Food and Drug Administration (FDA).
· He was recognized as a “Top Chief Medical Officer” in the United States for 2012 by ExecRank.
Industry Leadership and Contributions
· Founder and President of the International Exosome Association (IEXA).
· Chaired the first, second, and third IEXA Congresses (Beijing International Convention Center).
· Served as Chief Medical/Scientific Advisor to several prominent biotechnology, cell and gene therapy, and pharmaceutical companies, deeply involved in technology research and clinical development in areas such as cancer, pulmonology, immunotherapy, stem cell regenerative medicine, immune cell/gene therapy, and exosomes.
Leadership Philosophy and Vision
As Chief Medical Officer of Hong Kong Cell Valley Group, Dr. David Kin Jin is committed to providing patients with comprehensive, innovative, and effective medical solutions through advanced medical technology and rigorous clinical research, and to accelerating the global application of cell and gene therapy.
